The 36-month beta value for CMRX is also noteworthy at 0.35. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CMRX is 76.06M, and at present, short sellers hold a 4.69% of that float. The average trading volume of CMRX on February 27, 2025 was 5.03M shares.
CMRX) stock’s latest price update
The stock price of Chimerix Inc (NASDAQ: CMRX) has dropped by -1.50 compared to previous close of 4.67. Despite this, the company has seen a fall of -9.45% in its stock price over the last five trading days. seekingalpha.com reported 2025-02-20 that The company holds potential to have first approval of dordaviprone for the treatment of recurrent H3 K27M mutant high-grade glioma patients; PDUFA with Priority Review date of August 18th of 2025. The global brain tumor therapeutics market is expected to grow to $5.28 billion by 2030; the Company notes that it could obtain >$1 billion in revenues in the United States alone. Phase 3 ACTION study using dordaviprone for the treatment of front-line H3 K27M mutant high-grade glioma patients to have OS interim data readout in Q3 of 2025.
CMRX’s Market Performance
CMRX’s stock has fallen by -9.45% in the past week, with a monthly rise of 14.14% and a quarterly rise of 403.45%. The volatility ratio for the week is 6.79% while the volatility levels for the last 30 days are 6.79% for Chimerix Inc The simple moving average for the last 20 days is 4.30% for CMRX’s stock, with a simple moving average of 178.57% for the last 200 days.
Analysts’ Opinion of CMRX
Many brokerage firms have already submitted their reports for CMRX stocks, with Robert W. Baird repeating the rating for CMRX by listing it as a “Outperform.” The predicted price for CMRX in the upcoming period, according to Robert W. Baird is $7 based on the research report published on May 23, 2023 of the previous year 2023.
CapitalOne, on the other hand, stated in their research note that they expect to see CMRX reach a price target of $7. The rating they have provided for CMRX stocks is “Overweight” according to the report published on September 07th, 2022.
Maxim Group gave a rating of “Buy” to CMRX, setting the target price at $20 in the report published on April 29th of the previous year.
CMRX Trading at 20.96% from the 50-Day Moving Average
After a stumble in the market that brought CMRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.76% of loss for the given period.
Volatility was left at 6.79%, however, over the last 30 days, the volatility rate increased by 6.79%, as shares surge +13.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +54.36% upper at present.
During the last 5 trading sessions, CMRX fell by -9.45%, which changed the moving average for the period of 200-days by +373.93% in comparison to the 20-day moving average, which settled at $4.41. In addition, Chimerix Inc saw 32.18% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CMRX starting from Melemed Allen S., who sale 3,065 shares at the price of $4.50 back on Feb 13 ’25. After this action, Melemed Allen S. now owns 152,875 shares of Chimerix Inc, valued at $13,799 using the latest closing price.
Andriole Michael T., the PRESIDENT AND CEO of Chimerix Inc, sale 7,370 shares at $4.52 during a trade that took place back on Feb 13 ’25, which means that Andriole Michael T. is holding 609,603 shares at $33,282 based on the most recent closing price.
Stock Fundamentals for CMRX
Current profitability levels for the company are sitting at:
- -583.81 for the present operating margin
- -132.86 for the gross margin
The net margin for Chimerix Inc stands at -525.75. The total capital return value is set at -0.68. Equity return is now at value -48.59, with -43.54 for asset returns.
Based on Chimerix Inc (CMRX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -109.39. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -32.62.
Currently, EBITDA for the company is -92.97 million with net debt to EBITDA at 0.25. When we switch over and look at the enterprise to sales, we see a ratio of 2457.26. The receivables turnover for the company is 1.03for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.33.
Conclusion
In summary, Chimerix Inc (CMRX) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
